Biotech Stocks Flash Major Buy and Sell Signals: 15 Stocks to Watch as PACB Surges 106% and CRBU Plunges 60%

Biotech stocks are showing a sharp divergence in technical momentum, with several genomics, diagnostics and biotechnology companies flashing bullish signals while others face significant selling pressure. In the supplied stock screener snapshot, Pacific Biosciences (PACB) gained 106.06% over one month, while Caribou Biosciences (CRBU) declined 59.74% over the same period.

Meanwhile, Seer (SEER), Genmab (GMAB), CareDx (CDNA), Vaxcyte (PCVX), 908 Devices (MASS) and several other biotechnology-related stocks have strong positive technical scores supported by bullish momentum indicators.

However, not every Strong Buy signal represents an attractive entry opportunity. Some stocks are approaching overbought conditions, while others have limited potential rewards relative to their calculated downside risk.

For investors researching the best biotech stocks to watch in October 2026, the latest screener data provides important insights into market momentum, potential technical breakouts, weakening trends and stocks requiring additional caution.

Biotech Stocks October 2026: Key Highlights

• PACB: Recorded a 106.06% one-month gain, with RSI at 80.2.
• SEER: Technical score of 13, with bullish MACD and rising OBV.
• GMAB: Strong Buy technical rating, supported by ADX of 31.1.
• CDNA: Gained 116.56% over three months in the supplied data.
• PCVX: Strong Buy rating with a technical score of 12.
• MASS: Bullish indicators and an ADX reading of 43.4.
• CRBU: Technical score of -15 following severe price weakness.
• GPCR: RSI of 15.6 and ADX of 49.0 indicate extreme weakness within a strong trend.

Quick takeaway: Several diagnostics, genomics and biotechnology stocks are exhibiting positive technical momentum. However, sharp losses in other names demonstrate why stock selection and risk management remain essential.

Top 15 Biotech Stocks to Watch in October 2026

The following stocks stand out for their positive technical scores, momentum indicators or improving technical setups in the supplied screener.

Source: Supplied technical screener snapshot. These are model-generated technical classifications, not investment analyst consensus ratings. The list is organized editorially and does not represent a validated forecast of future performance.

1. Pacific Biosciences (PACB): Powerful Rally Comes With Overbought Risk

Pacific Biosciences is among the most notable momentum stocks in the supplied biotechnology dataset.

PACB trades at $2.72 in the snapshot after recording a 106.06% one-month gain and a 68.94% three-month advance.

• Stock price: $2.72
• RSI: 80.2
• MACD: Bullish
• ADX: 45.9
• Technical score: 13
• 50-day SMA: $1.51
• 200-day SMA: $1.59
• Calculated first target: $3.20
• Calculated stop loss: $2.36

Why PACB's Technical Momentum Stands Out

PACB's bullish MACD, rising OBV and strong directional indicators point to substantial buying momentum in the snapshot.

Its ADX of 45.9 indicates a strong trend, while its positive directional indicator of 49.0 is significantly higher than its negative directional indicator of 2.5.

However, its RSI of 80.2 signals overbought conditions. The stock is also trading substantially above its 50-day and 200-day moving averages.

Technical outlook: PACB has strong momentum but elevated short-term pullback risk. Investors should distinguish between an established rally and a favorable new entry.

2. Seer (SEER): Bullish Momentum With a Strong Technical Score

Seer is another genomics-related stock showing constructive technical indicators.

SEER has a technical score of 13, an RSI of 61.7 and an ADX reading of 26.1.

Its bullish MACD, rising OBV and positive directional indicators support an upward technical trend.

SEER Technical Levels

• Price: $2.21
• 50-day SMA: $2.04
• 200-day SMA: $1.91
• Target 1: $2.41
• Target 2: $2.51
• Stop loss: $2.06

The stock trades above both moving averages, while the 50-day average is above the 200-day average.

That combination supports a positive technical structure, although the calculated risk-to-reward ratio of 1.3:1 remains below a commonly used 2:1 threshold.

3. Genmab (GMAB): Strong Trend and Rising Volume Indicators

Genmab has a technical score of 13, supported by a bullish MACD, rising OBV and an ADX reading of 31.1.

GMAB trades at $36.65 in the screener, with an RSI reading of 60.7.

The stock is above its 50-day moving average of $33.20 and 200-day moving average of $29.72.

Its one-month and three-month returns are 9.31% and 23.07%, respectively.

The screener provides a first technical target of $39.19 and a second target of $40.46.

Technical outlook: GMAB shows positive trend strength and momentum alignment. However, its listed preferred entry range remains below the quoted price, making entry discipline important.

4. CareDx (CDNA): Strong Three-Month Momentum

CareDx is among the strongest longer-period performers in the supplied healthcare and diagnostics group.

CDNA gained 116.56% over the three-month period shown in the screener.

The stock carries a technical score of 13 and an ADX reading of 57.6, indicating unusually strong directional trend strength.

• Price: $63.04
• RSI: 61.3
• MACD: Bullish
• OBV trend: Rising
• Target 1: $69.99
• Target 2: $73.47
• Stop loss: $57.83

Although the momentum indicators remain positive, CDNA is trading above the screener's preferred entry range of $46.34 to $59.04.

This means its current technical strength should not be confused with an opportunity to buy at the original suggested entry price.

5. Vaxcyte (PCVX): Strong Buy Technical Rating

Vaxcyte carries a technical score of 12, an RSI of 61.0 and an ADX reading of 27.4.

The supplied dataset shows positive MACD momentum, rising OBV and bullish directional indicators.

PCVX trades at $66.96, above its 50-day moving average of $59.39 and its 200-day moving average of $55.52.

Its calculated targets are $76.36 and $81.05, with a listed stop-loss level of $59.91.

Watch point: Sustained relative strength and trading volume may be important for confirming whether the positive technical structure continues.

6. AI Drug Discovery Stocks: RXRX, EXAI and DNA

Artificial intelligence-driven drug discovery is another closely watched area of biotechnology investing.

Companies applying computational models, biological datasets and automation to drug research can attract considerable investor attention, but their stock prices remain sensitive to financing, clinical progress and business fundamentals.

Recursion Pharmaceuticals (RXRX)

RXRX has a technical score of 9 and a bullish MACD reading in the screener.

The stock is priced at $4.27, with a one-month return of 24.13% and an ADX reading of 32.8.

The screener classifies RXRX as a Strong Buy, with a calculated first target of $4.93.

However, falling OBV indicates that not every volume-based signal supports the bullish picture.

Exscientia (EXAI)

The supplied EXAI row shows a price of $1.64, a technical score of 10 and an RSI reading of 56.6.

Its positive MACD and rising OBV suggest improving momentum in the raw snapshot.

Data qualification: This ticker requires independent listing-status verification before being treated as a currently tradable security. The row is included for dataset analysis only.

Ginkgo Bioworks (DNA)

DNA carries a score of 8, a bullish MACD and an ADX reading of 52.9.

Its supplied one-month return stands at 65.27%, while its three-month return is 17.88%.

Despite that positive momentum, the stock also shows high historical volatility. Investors should monitor liquidity and price fluctuations carefully.

7. Biotech Stocks With the Biggest Momentum Gains

Several stocks experienced substantial percentage moves over the one-month or three-month periods shown in the screener.

Important: Strong historical returns do not imply that a stock will continue rising. Some of the biggest gainers also have elevated volatility or weak short-term confirmation.

8. Biotech Stocks Flashing Strong Sell Signals

While several biotech-related stocks exhibit bullish momentum, others face substantial technical weakness.

The supplied data indicates that Caribou Biosciences (CRBU), Foghorn Therapeutics (FHTX), Structure Therapeutics (GPCR), Seres Therapeutics (MCRB) and other companies have negative technical scores accompanied by bearish momentum.

Caribou Biosciences (CRBU): Extreme Oversold Reading

CRBU has one of the weakest technical profiles in the dataset.

The stock fell 45.61% in the supplied daily-change field, with a one-month decline of 59.74%.

Its RSI of 12.8 signals extremely oversold conditions, while its ADX reading of 37.5 points to strong trend intensity.

The negative directional indicator of 59.2 is substantially higher than the positive directional indicator of 5.8, suggesting the prevailing trend is bearish.

Technical outlook: CRBU is severely oversold, but the supplied indicators do not establish a confirmed reversal. Oversold conditions can persist during major downtrends.

Structure Therapeutics (GPCR): Bearish Trend Strength

GPCR has an RSI reading of 15.6 and an ADX of 49.0.

Its technical score of -14, bearish MACD and falling OBV indicate broad negative technical alignment.

The screener shows a one-month loss of 33.93% and a three-month decline of 51.61%.

Investors looking for a reversal would typically want to see improving price action and confirmation from momentum indicators before treating an oversold reading as a buy signal.

Foghorn Therapeutics (FHTX): Strong Downtrend

FHTX has an RSI of 16.3, a bearish MACD and an ADX reading of 51.8.

Its one-month decline of 56.73% highlights the severity of recent weakness shown in the snapshot.

The supplied technical classification is Strong Sell, with no confirmed entry setup.

9. Gene Editing Stocks: EDIT, BEAM and NTLA

Gene editing is a closely followed area of biotechnology, but related stocks can follow very different price trends despite their connection to similar technologies.

Editas Medicine (EDIT)

EDIT has a technical score of 3 and a bullish MACD.

The stock trades at $2.75 in the supplied dataset, with an RSI of 49.8 and rising OBV.

Its calculated first target is $2.84, while the listed stop loss is $2.47.

The corresponding risk-to-reward ratio is only 0.3:1, indicating that the nearby first target provides relatively limited upside compared with potential downside.

Beam Therapeutics (BEAM)

BEAM trades at $24.77, with a neutral overall technical score of 0.

Its MACD is bullish, but its OBV trend is falling and ADX stands at 14.5, indicating limited established trend strength.

The screener shows five of six entry conditions met, yet the overall technical classification remains Hold.

This illustrates why a high number of entry conditions alone should not override conflicting indicators.

Intellia Therapeutics (NTLA)

NTLA has a technical score of 3, a bullish MACD and rising OBV.

However, the stock's price of $11.71 sits below its 50-day moving average of $12.11 and its 200-day moving average of $12.90.

The screener reports a Strong Entry classification but a risk-to-reward ratio of just 0.3:1.

Technical takeaway: EDIT, BEAM and NTLA show some positive momentum indicators, but their overall setups remain mixed.

10. Biotech Stocks With Strong Entry Classifications

The screener identifies several stocks where five of six entry conditions are satisfied.

These signals may help investors build a watchlist, but each setup still requires verification of current prices, risk-to-reward ratios and technical confirmation.

Risk warning: The model confidence percentages are not verified statistical probabilities of profitable trades. Moreover, every setup in this table has a supplied risk-to-reward ratio below 2:1, so the Strong Entry label should not be interpreted as an unconditional buying recommendation.

11. Biotech Stock Price Targets and Stop-Loss Levels

Here are selected technical target and stop-loss levels from the supplied dataset.

These targets are calculated technical reference levels, not analyst price targets or guarantees. A stop-loss order does not guarantee an execution price in a volatile market.

12. What Technical Indicators Matter Most for Biotech Stocks?

Biotechnology stocks can react sharply to clinical trial announcements, regulatory decisions, product launches, acquisitions and financing developments.

Because of these risks, investors should evaluate technical indicators alongside fundamental research.

Relative Strength Index (RSI)

RSI measures momentum on a scale from 0 to 100.

• Above 70: Commonly considered overbought.
• 30 to 70: Broad neutral range.
• Below 30: Commonly considered oversold.

For example, PACB's RSI of 80.2 suggests strong but extended momentum, while CRBU's RSI of 12.8 indicates extreme selling pressure.

MACD

MACD helps identify momentum changes. A bullish reading can indicate improving short-term momentum, while a bearish reading may suggest weakening price action.

Average Directional Index (ADX)

ADX measures trend strength, not trend direction.

Readings above 25 often indicate an established trend. Investors should also check whether +DI or -DI is dominant.

Moving Averages

The 50-day and 200-day moving averages provide context on intermediate and longer-term price trends.

A stock trading above both averages may have a constructive technical structure, although moving averages are lagging indicators.

On-Balance Volume (OBV)

OBV tracks buying and selling participation through cumulative trading volume.

Rising OBV may support bullish momentum, while falling OBV can warn of weaker buying participation.

13. Why Biotech Stocks Can Be Especially Volatile

Biotechnology investing carries risks that extend beyond traditional technical chart analysis.

Clinical-stage companies may experience major price changes following trial results, regulatory announcements or financing events.

Investors should consider the following factors before buying biotech stocks:

• Clinical trial results: Unexpected efficacy or safety findings can materially affect valuations.
• FDA and regulatory decisions: Approvals, delays or rejections can trigger sharp moves.
• Cash runway: Companies with limited cash reserves may require additional financing.
• Share dilution: Equity offerings can reduce existing shareholders' ownership percentages.
• Trading liquidity: Smaller biotechnology stocks may experience wide spreads and sharp price gaps.
• Product concentration: Reliance on a small number of drug candidates may increase company-specific risk.

Technical analysis can identify trends, but it cannot reliably anticipate every clinical or regulatory catalyst.

14. What Should Investors Watch Next?

Based on the supplied screener, investors researching biotechnology stocks may want to follow several developments.

• PACB: Whether momentum continues or the overbought RSI produces a pullback.
• SEER and GMAB: Whether bullish MACD and volume trends remain intact.
• CDNA and PCVX: Whether trend strength is maintained above major moving averages.
• AI drug discovery stocks: Whether RXRX and DNA sustain their recent momentum.
• CRBU and GPCR: Whether extreme oversold readings begin developing genuine reversal confirmation.
• Gene editing stocks: Whether EDIT, BEAM and NTLA improve their broader technical alignment.

Final Outlook: Biotech Stocks Show Sharp Divergence

The latest supplied biotechnology screener shows a market divided between stocks with strong positive momentum and those experiencing severe technical weakness.

PACB, SEER, GMAB and CDNA stand out for their technical scores, while PCVX, MASS, IOVA and RXRX also show constructive readings.

At the opposite end, CRBU, GPCR, FHTX, MCRB and several other names exhibit deeply negative technical indicators.

The key lesson is that a biotechnology company's long-term scientific potential and its current technical outlook are different considerations.

Investors should focus on verified market prices, improving technical confirmation, clinical catalysts, financial condition and carefully defined risk limits rather than relying on a single Strong Buy or Strong Sell label.

Data Source and Methodology

This article analyzes a supplied biotechnology and healthcare stock screener containing RSI, MACD, ADX, directional indicators, OBV, moving averages, momentum returns, technical scores and calculated trading levels.

The values are treated as an unverified snapshot. Rows containing spreadsheet reference errors were excluded from the principal rankings. Duplicate observations were not counted as separate opportunities.

Potentially stale ticker symbols, delisted securities and company-action-related records require independent validation. Calculated targets and confidence values have not been independently backtested.

The dataset does not establish the underlying causes of individual stock moves. No clinical, regulatory or company-specific catalyst is assumed solely from a stock's price change.

Investment Disclaimer

This article is provided for educational and informational purposes only. It does not constitute financial advice, an offer to buy or sell securities, or a recommendation tailored to any investor.

Biotechnology stocks can be highly volatile and may result in substantial financial losses. Technical scores, confidence percentages, targets and stop-loss levels are not guarantees of future performance.

Readers should independently verify current market data and consult a qualified financial professional when appropriate.